BuSpar Appeal: Bristol Argues Mylan Evaded Waxman/Hatch By Filing Suit
Executive Summary
Mylan attempted to circumvent Waxman/Hatch procedures by filing suit against Bristol-Myers Squibb over its BuSpar (buspirone) metabolite patent before issuing a Paragraph IV certification, Bristol argued before the federal circuit appeals court in Washington D.C. July 12.
You may also be interested in...
BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending
FDA may consider returning generic buspirone ANDA approvals to tentative approval status as one option in light of an appellate court decision favoring Bristol-Myers Squibb in the BuSpar patent case.
BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending
FDA may consider returning generic buspirone ANDA approvals to tentative approval status as one option in light of an appellate court decision favoring Bristol-Myers Squibb in the BuSpar patent case.
Bristol BuSpar Pediatric Labeling May Delay Second Round Of Generics
The second round of generic approvals for Bristol's anti-anxiety drug BuSpar (buspirone) appears to be held up by Bristol's attempts to enforce exclusivity based on a change in labeling related to pediatric studies.